This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Clinical Trial

. 1974 Aug;4(4):373-8.

doi: 10.1111/j.1445-5994.1974.tb03207.x.

L-alpha-methyldopa hydrazine (Carbidopa) combined with L-dopa in the treatment of Parkinson's disease

G L Glasgow, J W Henley, E W Willoughby

PMID: 4278910
DOI: 10.1111/j.1445-5994.1974.tb03207.x

Clinical Trial

L-alpha-methyldopa hydrazine (Carbidopa) combined with L-dopa in the treatment of Parkinson's disease

G L Glasgow et al. Aust N Z J Med. 1974 Aug.

. 1974 Aug;4(4):373-8.

doi: 10.1111/j.1445-5994.1974.tb03207.x.

Authors

G L Glasgow, J W Henley, E W Willoughby

PMID: 4278910
DOI: 10.1111/j.1445-5994.1974.tb03207.x

No abstract available

PubMed Disclaimer

Similar articles

Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease.
Lieberman A, Goodgold A, Jonas S, Leibowitz M. Lieberman A, et al. Neurology. 1975 Oct;25(10):911-6. doi: 10.1212/wnl.25.10.911. Neurology. 1975. PMID: 1101099 Clinical Trial.
Alpha methyldopahydrazine as an adjunct to levodopa therapy in Parkinson's disease.
Paty DW, Jaatoul N, Kertesz A, McInnis W. Paty DW, et al. Can J Neurol Sci. 1975 Aug;2(3):169-72. doi: 10.1017/s0317167100020205. Can J Neurol Sci. 1975. PMID: 1100213 Clinical Trial.
Treatment of "on-off effect" with a dopa decarboxylase inhibitor.
Sweet RD, McDowell FH, Wasterlain CG, Stern PH. Sweet RD, et al. Arch Neurol. 1975 Aug;32(8):560-3. doi: 10.1001/archneur.1975.00490500080010. Arch Neurol. 1975. PMID: 1156214 Clinical Trial.
Recent advances in the treatment of Parkinson's disease.
Martocci RJ. Martocci RJ. J Am Osteopath Assoc. 1975 Apr;74(8):730-41. J Am Osteopath Assoc. 1975. PMID: 1092751 Review. No abstract available.
[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
Castro A, Valldeoriola F, Linazasoro G, Rodriguez-Oroz MC, Stochi F, Marin C, Rodriguez M, Vaamonde J, Jenner P, Alvarez L, Pavon N, Macias R, Luquin MR, Hernandez B, Grandas F, Gimenez-Roldan S, Tolosa E, Obeso JA. Castro A, et al. Neurologia. 2005 May;20(4):180-8. Neurologia. 2005. PMID: 15891947 Review. Spanish.

See all similar articles

Cited by

Metabogenomics reveals four candidate regions involved in the pathophysiology of Equine Metabolic Syndrome.
Patterson Rosa L, Mallicote MF, Long MT, Brooks SA. Patterson Rosa L, et al. Mol Cell Probes. 2020 Oct;53:101620. doi: 10.1016/j.mcp.2020.101620. Epub 2020 Jul 10. Mol Cell Probes. 2020. PMID: 32659253 Free PMC article.
Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS. Pinder RM, et al. Drugs. 1976;11(5):329-77. doi: 10.2165/00003495-197611050-00001. Drugs. 1976. PMID: 782834 Review. No abstract available.
Emerging Role of l-Dopa Decarboxylase in Flaviviridae Virus Infections.
Frakolaki E, Kalliampakou KI, Kaimou P, Moraiti M, Kolaitis N, Boleti H, Koskinas J, Vassilacopoulou D, Vassilaki N. Frakolaki E, et al. Cells. 2019 Aug 5;8(8):837. doi: 10.3390/cells8080837. Cells. 2019. PMID: 31387309 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Wiley